CB2 cannabinoid receptor agonist ameliorates novel object recognition but not spatial memory in transgenic APP/PS1 mice


BIBLIOGRAPHIC THERAPEUTIC AGENT ANIMAL MODEL EXPERIMENTAL DESIGN OUTCOMES

Bibliographic

Year of Publication:
2019
Contact PI Name:
Huiqun Jia
Contact PI Affiliation:
Department of Anesthesiology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Co-Authors:
Chao Li, Jingpu Shi, Bo Wang, Jin Li
Primary Reference (PubMED ID):
Funding Source:
National Natural Science Foundation of China
Municipal Science and Technology Commission Project of China
Study Goal and Principal Findings:

The cannabinoid receptor 2 (CB2R) has been considered as a potential therapeutic target to ameliorate the neuroinflammation and cognitive impairments of Alzheimer’s disease (AD). However, there has been little research on the diverse roles of CB2R in regulating different forms of cognitive abilities and underlying neuroinflammatory mechanisms. Thus, the focus of the present study was to investigate the effects of CB2R activation on cognitive abilities, activation and phenotype conversion of microglia, and dendrite complexity. Results showed that CB2R activation normalized the cortex-dependent novel object recognition memory deficit in a novel object recognition test (P < 0.05) and CB2R activation was ineffective for hippocampus-dependent spatial cognitive dysfunction in the Morris water maze test (P > 0.05). Moreover, activation of CB2R did not affect the formation of plaque in either the cortex or hippocampus (P > 0.05). Interestingly, in the cortex but not in the hippocampus of APP/PS1 mice, there was decreased immunofluorescence intensity of Iba1, M1 to M2 microglial phenotype conversion, and restored dendritic complexity after a long treatment period of CB2R agonist (All P < 0.05). Our results demonstrated that CB2R activation exerts a beneficial role in novel object recognition ability concomitant with region-specific regulation in microglia-mediated neuroinflammation and dendritic complexity in AD-model mice.

Therapeutic Agent

Therapeutic Information:
Therapy Type:
Small Molecule
Therapeutic Agent:
JHW-015
Therapeutic Target:
Cannabinoid Receptor 2 (CB2)

Animal Model

Model Information:
Species:
Mouse
Model Type:
APPxPS1
Strain/Genetic Background:
C57BL/6J

Experimental Design

Is the following information reported in the study?:
Power/Sample Size Calculation
Randomized into Groups
Blinded for Treatment
Blinded for Outcome Measures
Pharmacokinetic Measures
Pharmacodynamic Measures
Toxicology Measures
ADME Measures
Biomarkers
Dose
Formulation
Route of Delivery
Duration of Treatment
Frequency of Administration
Age of Animal at the Beginning of Treatment
Age of Animal at the End of Treatment
Sex as a Biological Variable
Study Balanced for Sex as a Biological Variable
Number of Premature Deaths
Number of Excluded Animals
Statistical Plan
Genetic Background
Inclusion/Exclusion Criteria Included
Conflict of Interest

Outcomes

Outcome Measured
Outcome Parameters
Behavioral
Novel Object Recognition Test (NORT)
Morris Water Maze
Histopathology
Congophillic Amyloid Deposits
Biochemical
Interleukin 6 (IL-6) mRNA
Tumor Necrosis Factor alpha (TNF alpha) mRNA
Inducible Nitric Oxide Synthase (iNOS/NOS2) mRNA
M2 Microglial Marker (Ym1/2) mRNA
Immunochemistry
Ionized Calcium Binding Adaptor Molecule 1 (Iba1)
Microscopy
Dendritic Spine Density
Dendritic Spine Morphology
Dendritic Spines
Dendritic Spine Number
Dendritic Length
Dendritic Arborization

Source URL: http://alzped.nia.nih.gov/cb2-cannabinoid-receptor